Aligos stockholders approve charter amendments increasing authorized shares 5x and 2020 Plan share reserve by 1M

Aligos Therapeutics, Inc.

Stockholders approved increase in authorized voting common stock from 20M to 100M shares.
Stockholders approved increase in authorized non-voting common stock from 800k to 15.8M shares.
Stockholders approved amendment to 2020 Plan adding 1M shares to the share reserve.
All three Class II director nominees (Hirth, Preston, Chavez) were elected with ~2.16M votes for.
Ratification of Ernst & Young as independent auditor for FY2025 approved with 3.43M votes for.

Key facts

Extracted from this filing and checked against the source text.

Governance Changes SEC 8-K Item 5.03/5.05/5.06 confidence 0.9

Aligos Therapeutics, Inc.: Increased authorized shares of voting common stock from 20,000,000 to 100,000,000 and non-voting common stock from 800,000 to 15,800,000 (effective 2025-06-25).

Change: charter amendment
Effective: 2025-06-25

Exact text from the filing

The increase in the number of authorized shares voting common stock and non-voting common stock was effected pursuant to a Certificate of Amendment to the Amended and Restated Certificate of Incorporation (the “Certificate of Amendment”) filed with the Secretary of State of the State of Delaware on June 25, 2025 and was effective as of such date.

View on SEC.gov

Browse all governance changes →

Aligos Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-25-148905

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.